Published mark
Alzamend Neuro, Inc.
NASDAQ: ALZN. Canonical company identity and public leadership record.
US
Record source reportedRecord not claimedNo Eval published
- Alpha ID
- alpha:company:5b6352c0-54b0-45af-8d6d-a6e478461035
- SEC CIK
- 0001677077
- Record version
- vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce, published Oct 19, 2026
- Newest evidence
- Feb 26, 2026
- Monitoring
- Not yet monitored Details
- Integrity
- Not yet signed Methodology
- CEO
- Stephan JackmanChief Executive Officer
- Chair
- Not published
- Independent
- Not published7 directors published
- Published claims
- 263 distinct sources
- Evidence records
- 50 pinned
- Source conflicts
- 0None open
Built from 3 distinct sources and 5 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.
CorroboratedSource reportedAlpha inferenceNot disclosed
Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works
DIRECTOR APPOINTED
Henry Nisser seat on Alzamend Neuro, Inc., effective 2026-02-26.
EffectiveEffective Feb 26, 2026E2
Monitoring
ContinuousWhat the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.
- IdentityunclaimedPublished
- Evidencesource_reportedPublished
- Evaluationnot_evaluatedPublished
- MonitoringNot yet published for this record.Not published
- AuthorityNot yet published for this record.Not published
- FreshnesscurrentPublished
Leadership
Evidence| Role | Person | Since | Status | Claim |
|---|---|---|---|---|
| Senior Vice President of Finance | Kenneth S. Cragun | Jul 2025 | current | Source reportedE4 |
| Chief Financial Officer | David J. Katzoff | Not captured | unknown | Source reportedE3 |
| Executive Vice President and General Counsel | Henry Nisser | Not captured | unknown | Source reportedE3 |
| Chief Executive Officer | Stephan Jackman | Not captured | unknown | Source reportedE3 |
Board of directors
Evidence7 directors published. Independence determinations are not published for every director.
| Director | Status | Since | Committees | Claim |
|---|---|---|---|---|
| Henry Nisser | Independence not published | 2026 | None published | Source reportedE2 |
| Jeffrey Oram | Independence not published | 2026 | Audit Committee, chaircompensation committee, chairNominating and Corporate Governance Committee, chair | Source reportedE2 |
| Lynne F. McGrath | Independence not published | 2026 | compensation committeeNominating and Corporate Governance Committee | Source reportedE2 |
| Mark Gustafson | Independence not published | 2026 | Audit Committeecompensation committee | Source reportedE2 |
| Milton C. Ault | Independence not published | 2024 | None published | Source reportedE2 |
| Stephan Jackman | Independence not published | 2026 | None published | Source reportedE2 |
| WILLIAM B. HORNE | Independence not published | 2016 | Audit Committee | Source reportedE2 |
Committees and risk ownership
Evidence| Committee | Chair | Members | Risks assigned |
|---|---|---|---|
| Audit Committee | Jeffrey Oram | Jeffrey Oram, Mark Gustafson, WILLIAM B. HORNE | Not described in the published record |
| compensation committee | Jeffrey Oram | Jeffrey Oram, Lynne F. McGrath, Mark Gustafson | Not described in the published record |
| Nominating and Corporate Governance Committee | Jeffrey Oram | Jeffrey Oram, Lynne F. McGrath | Not described in the published record |
Committee RecordAudit Committee: Chair Jeffrey Oram; Members Jeffrey Oram (Chair); Mark Gustafson; WILLIAM B. HORNE
Committee AppointmentJeffrey Oram: chair, Audit Committee
Committee AppointmentMark Gustafson: member, Audit Committee
Committee AppointmentWILLIAM B. HORNE: member, Audit Committee
Committee Recordcompensation committee: Chair Jeffrey Oram; Members Jeffrey Oram (Chair); Lynne F. McGrath; Mark Gustafson
Committee AppointmentJeffrey Oram: chair, compensation committee
Committee AppointmentLynne F. McGrath: member, compensation committee
Committee AppointmentMark Gustafson: member, compensation committee
Committee RecordNominating and Corporate Governance Committee: Chair Jeffrey Oram; Members Jeffrey Oram (Chair); Lynne F. McGrath
Committee AppointmentJeffrey Oram: chair, Nominating and Corporate Governance Committee
Committee AppointmentLynne F. McGrath: member, Nominating and Corporate Governance Committee
Control and voting power
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Authority to act
Evidence and agent registryWho can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.
Principal executive officerStephan Jackman, Chief Executive Officer
Who can authorize an agentNot assessedNo Alpha inference about signing authority or board-reserved matters is published for this record.
Not assessed
AI agents registered by the companyNot registered in the public RegistryAgent Deployments, Agent Use Cases, Authority Grants, TrustChecks, Action Ledger entries and Governance Receipts live in the private enterprise overlay. They are never projected into the public Registry without explicit cross-plane authorization. Absence here is a plane boundary, not evidence that the enterprise operates no agents.
Agent registry
Delegations publishedNot disclosedBoard and officer delegation resolutions are not public filings and are not published in this record.
Search scope
Financials and market context
EvidenceSecurity ListingALZN (NASDAQ)
Index membershipsNo current membership is published in Alpha's tracked index universe.This is not evidence that the company is absent from every market index.
None publishedAs of Oct 19, 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.
Governance and policies
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Risk, audit, and cyber
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
AI oversight and accountability
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Legal and regulatory
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Compensation
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Other published claims
EvidencePublished Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.
Legal NameAlzamend Neuro, Inc.
Entity StatusPublic listing published
Published FactUS
Not yet in this record
CoverageA gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.
- Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
- OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
- FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
- CompensationNot reviewed. Pay design shows how incentives are governed.
- GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
- Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
- AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
- LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
- RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
- CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
- AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
- Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
- Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
- Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
- Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
- Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
- This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.
Linked people
Same claims as person records- Kenneth S. CragunSenior Vice President of Financecompany:5b6352c0-54b0-45af-8d6d-a6e478461035:leadership_role:14
- David J. KatzoffChief Financial Officercompany:5b6352c0-54b0-45af-8d6d-a6e478461035:leadership_role:12
- Henry NisserExecutive Vice President and General Counsel; Directorcompany:5b6352c0-54b0-45af-8d6d-a6e478461035:leadership_role:13, company:5b6352c0-54b0-45af-8d6d-a6e478461035:leadership_role:5
- Stephan JackmanChief Executive Officer; Directorcompany:5b6352c0-54b0-45af-8d6d-a6e478461035:leadership_role:15, company:5b6352c0-54b0-45af-8d6d-a6e478461035:leadership_role:10
- Jeffrey OramDirectorcompany:5b6352c0-54b0-45af-8d6d-a6e478461035:leadership_role:6
- Lynne F. McGrathDirectorcompany:5b6352c0-54b0-45af-8d6d-a6e478461035:leadership_role:7
- Mark GustafsonDirectorcompany:5b6352c0-54b0-45af-8d6d-a6e478461035:leadership_role:8
- Milton C. AultDirectorcompany:5b6352c0-54b0-45af-8d6d-a6e478461035:leadership_role:9
- WILLIAM B. HORNEDirectorcompany:5b6352c0-54b0-45af-8d6d-a6e478461035:leadership_role:11
Subject and corrections
Public-role doctrineThis record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.
- Basis
- Published company record built from public sources
- Sources
- 5 evidence records cited. 0 with redistribution rights.
- Never published
- Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
- Record claimed
- No
- Open disputes
- 0
- Identity ownership
- unclaimed
Claiming not yet available
If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.
Evidence
Authority and rights- E1Alpha canonical company public projection. canonical identity. Retrieved Oct 19, 2026. Cited by 4 Claims.
- E2sec proxy. Published Feb 26, 2026. Retrieved Sep 2, 2026. Cited by 7 Claims.
- E3sec def 14a. Published Feb 26, 2026. Retrieved Sep 2, 2026. Cited by 3 Claims.
- E4sec filing. Published Jul 22, 2025. Retrieved May 15, 2026. Cited by 1 Claim.
- E5governance_people_committees. sec proxy. Cited by 11 Claims.
What changed in version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce
vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce published Oct 19, 2026- Henry Nisser seat on Alzamend Neuro, Inc., effective 2026-02-26.
- Jeffrey Oram seat on Alzamend Neuro, Inc., effective 2026-02-26.
- Lynne F. McGrath seat on Alzamend Neuro, Inc., effective 2026-02-26.
- Mark Gustafson seat on Alzamend Neuro, Inc., effective 2026-02-26.
- Stephan Jackman seat on Alzamend Neuro, Inc., effective 2026-02-26.
- Kenneth S. Cragun executive of Alzamend Neuro, Inc., effective 2025-07-22.
- Milton C. Ault seat on Alzamend Neuro, Inc., effective 2024-01-01.
- WILLIAM B. HORNE seat on Alzamend Neuro, Inc., effective 2016-01-01.